• 대한수의학회지
• /
• 제57권1호
• /
• pp.55-57
• /
• 2017

A 5-year-old, 2.7 kg, spayed female Scottish Fold cat presented with hematemesis after administration of oral zaltoprofen, a non-steroidal anti-inflammatory drug, by the owner. Diagnostic imaging and blood analyses indicated development of acute kidney injury (AKI) resulting from zaltoprofen ingestion. To correct dehydration and anemic conditions, the cat received intravenous fluid therapy with whole blood transfusion and peroral N-acetylcysteine. Clinical signs resolved, but persistent azotemia was unresolved indicating that AKI could progress to chronic kidney disease. This case suggests that although zaltoprofen may have low adverse effects on humans, administration of zaltoprofen in cats can have serious adverse effects.

• 폴리머
• /
• 제34권4호
• /
• pp.300-305
• /
• 2010

잘토프로펜(zaltotprofen)은 통증 치료와 염증 억제에 주로 사용되는 비스테로이드성 약물로, 류머티스 관절염 치료 및 해열 진통에 효능을 나타내는 약물이다. 잘토프로펜은 물에는 거의 녹지 않는 난용성 약물이다. 이러한 난용성 을 개선하여 흡수율을 증진시키고 생체이용률이 향상된 제제를 제공하기 위하여 여러 첨가제를 이용하여 타블렛으로 제 조하였다. 첨가제로는 락토스, 히드록시프로필메틸셀룰로오스(HPMC), 카복시메틸셀룰로오스(CMC)를 사용하였고 제조된 약물의 구조와 결정화도의 변화를 FTIR과 DSC를 이용하여 분석하였다. 시판제제인 솔레톤정$^{(R)}$과 비교하여 생 체외 방출 거동 실험을 하였고 실험결과 전체적으로 초기 약물 방출을 줄일 수 있었고 점차 방출률이 늘어나 시판제 제보다 더 높은 약물 방출을 보였다. 저점도의 HPMC는 고점도의 HPMC를 첨가했을 때보다 더 높은 약물 방출을 보였고 CMC의 양이 많아질수록 또한 약물 방출이 높게 나타났다.

• 폴리머
• /
• 제37권6호
• /
• pp.702-710
• /
• 2013

서방성방출을 위해 잘토프로펜을 함유한 미립구를 oil-in-water(O/W) 에멀젼용매 증발법을 이용하여 제조하였다. 제조온도, 교반속도, 초음파분쇄기의 강도, 약물농도, POX의 분자량과 농도, 유화제 농도 등의 제조조건에 따른 잘토프로펜의 방출거동을 평가하였다. 잘토프로펜을 함유한 POX 미립구의 물리화학적 성질 및 형태를 X선 회절분석법(XRD)과 시차주사열량계(DSC), 적외선 분광분석기(FTIR), 주사현미경(SEM)을 통해 연구하였다. 이러한 연구 결과로부터 제조조건들에 따른 미립구의 특성을 확인할 수 있었다. 또한 POX 미립구의 분해성을 10일 동안 in vitro 실험을 통해 조사하였다. 본 연구를 통해 잘토프로펜을 함유한 POX 미립구를 최적화된 용매증발방법으로 제조하였고, 이 미립구로부터 약물의 방출제어를 확인할 수 있었다.

• Journal of Pharmaceutical Investigation
• /
• 제36권3호
• /
• pp.209-215
• /
• 2006

Zaltoprofen, (2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic acid) is an NSAID with powerful anti-inflammatory effects as well as an analgesic action on inflammatory pain. The purpose of the present study was to evaluate the bioequivalence of two zaltoprofen tablets, $Soleton^{\circledR}$ (CJ Corp.) and SCD Zaltoprofen (Samchundang Pharmaceutical Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of zaltoprofen from the two zatoprofen formulations in vitro was tested using KP Vlll Apparatus ll method with various dissolution media. Twenty six healthy male subjects, $23.2{\pm}2.26$ years in age and$64.7{\pm}8.08$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After a single tablet containing 80 mg as zaltoprofen was orally administered, blood samples were taken at predetermined time intervals and the concentrations of zaltoprofen in serum were determined using HPLC with UV detector. The dissolution profiles of two formulations were similar in all tested dissolution media. The pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated, and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Soleton^{\circledR}$ were 6.33, 5.91 and 17.7% for $AUC_t$, $C_{max}$ and untransformed $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g.,log $1.01{\sim}1og\;1.11$ and log $0.928{\sim}1og\;1.18$ for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating SCD Zaltoprofen tablet was bioequivalent to $Soleton^{\circledR}$ tablet.

• 대한임상독성학회지
• /
• 제17권1호
• /
• pp.32-37
• /
• 2019

Kounis syndrome is defined as the occurrence of acute coronary syndrome associated with vasoactive mediators, such as histamines in the setting of hypersensitivity and allergic reactions or anaphylactic insults. The condition can be caused by various drugs, foods, or environmental factors that cause allergic reactions. A 35-year-old male visited the emergency room with anaphylaxis accompanied by chest pain approximately 20 minutes after taking zaltoprofen, a nonsteroidal anti-inflammatory drug. After acute treatment for the anaphylaxis, the patient was stabilized and all symptoms disappeared, but the ischemic changes in the electrocardiogram and elevation of the cardiac enzymes were observed. The emergency cardiac angiography and echocardiography were all normal. The allergic reaction of this patient to zaltoprofen was believed to cause a temporary coronary arterial vasospasm, inducing Type 1 Kounis syndrome. Thus far, there have been case reports of Kounis syndrome caused by a range of nonsteroidal anti-inflammatory drugs, but there are no reports of the condition being caused by zaltoprofen. According to the pathophysiology, both cardiac and allergic symptoms must be solved simultaneously, so rapid treatment and diagnosis are needed. Doctors treating acute allergic reactions and anaphylaxis patients must check the cardiovascular symptoms thoroughly and consider the possibility of Kounis syndrome.

• 폴리머
• /
• 제37권1호
• /
• pp.28-33
• /
• 2013

잘토프로펜은 프로피온산 유도체인 비스테로이드성 소염진통제로서 카라기난, 나이스타틴에서 유발된 급성염증에 큰 억제 효과를 가지고 있을 뿐만 아니라 급성 및 만성 염증에도 효과를 가지고 있다. 초기 방출 및 지속적인 방출을 위해서 잘토프로펜이 함유된 폴리옥살레이트(POX)와 PLGA 미립구를 각각 O/W 용매증발법으로 제조 후 각각의 미립구의 혼합비율을 달리하였다. 주사현미경, X선 회절 분석법, 시차 주사 열량계, 그리고 적외선 분광 분석기를 이용하여 잘토프로펜이 함유된 미립구의 물리화학적 성질 및 표면형태를 조사하였다. POX 미립구의 혼합비율이 증가할수록 초기 약물방출이 증가하며, PLGA 미립구의 혼합비율이 증가할수록 느린 약물방출을 보인다. 본 연구에서 초기 약물방출량이 높은 POX 미립구를 PLGA 미립구와 혼합비율을 조절함으로써 약물이 함유된 미립구의 초기방출 계수를 제어할 수 있을 것으로 사료된다.

• 폴리머
• /
• 제34권4호
• /
• pp.333-340
• /
• 2010

잘토프로펜은 프로피온산 유도체인 비스테로이드성 소염진통제로서 아급성 및 만성염증에 큰 억제 효과를 가지고 있다. 지속적인 약물의 방출을 위해서 PLGA의 분자량과 보조계면활성제의 농도를 달리하여 O/W 용매 증발법에 의해 잘토프로펜이 함유된 PLGA 미립구를 제조하였다. 잘토프로펜이 함유된 PLGA 미립구의 물리화학적 성질 및 표면형태를 조사하기 위해 주사현미경, X선 회절 분석법 그리고 시차 주사 열량계를 이용하였다. PLGA 분자량과 보조계면활성제의 농도가 증가할수록 미립구의 크기도 증가한다. PLGA 분자량과 보조계면활성제의 농도 가 증가할수록 미립구의 다공성이 줄어들고, 느린 약물의 방출을 보인다. 본 연구에서는 PLGA의 분자량과 보조계 면활성제의 농도를 조절하여 약물이 함유된 미립구의 방출 계수를 제어할 수 있을 것으로 사료된다.

• Korean Journal of Acupuncture
• /
• 제37권1호
• /
• pp.14-23
• /
• 2020

Objectives : We investigated the efficacy and safety of miniscalpel acupuncture (MA) treatment combined with non-steroidal anti-inflammatory drugs (NSAIDs) for chronic neck pain (CNP) in an assessor-blinded randomized controlled pilot trial to establish a basis for larger-scale randomized controlled studies on this subject. Methods : Participants (n=36) were recruited and randomly allocated to the MA group, NSAIDs and combined treatment group. The MA group received MA three times over three weeks. The NSAIDs group was administered orally with zaltoprofen 80mg t.i.d. over three weeks. The combined treatment group received MA and zaltoprofen in the same manner as MA and NSAIDs groups. The primary outcome was pain as assessed by a visual analogue scale (VAS) and the secondary outcomes were assessed using the Neck Disability index (NDI), EuroQol 5-dimension questionnaire (EQ-5D), and Patients' Global Impression of Change scale (PGIC). Assessments were made at week 0 (baseline), 1, 2, 3 (primary end point) during treatment and at week 7 (4 weeks after the end of treatment). Results : 35 participants completed the study. No serious adverse event occurred and blood test results were within normal limits. The improvement of VAS and NDI was significantly greater in combined and MA group than that in NSAIDs group (p<0.017). The combined group showed better outcomes in EQ-5D at visit 2 and 5, in PGIC at visit 4 than the NSAIDs group (p<0.017). No significant differences were found between combined and MA group. Conclusions : Our results suggest that both combined and MA group can be more effective in improving pain control than NSAIDs group. A large-scale clinical study is warranted to further clarify these findings.